Evaluation 2 (FAME 2) trial, a large randomized controlled trial evaluating patients with AP, cardiovascular events were significantly reduced in the fractional flow reserve (FFR)-guided PCI group. 3,4 The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, however, a large randomized controlled trial evaluating patients with AP, showed no difference in cardiovascular events between PCI and medical therapy. 5 The initial PCI method for STEMI differs to that for AP. That is, primary PCI is performed for STEMI patients while FFR-guided PCI is performed for AP patients. Consequently, the cost-effectiveness of PCI should be evaluated separately for STEMI and AP. Variable results have been reported for the cost-effectiveness of PCI over medical treatment for STEMI and AP. 6-14 Many studies showed that PCI in STEMI was cost-effective compared with medical therapy, 6-9 and some studies reported that PCI for AP was cost-effective compared with medical therapy, whereas others reported PCI for AP was not cost-effective.
Background:The cost-effectiveness of percutaneous coronary intervention (PCI) for ischemic heart disease is undetermined in Japan. The aim of this study was to analyze the cost-effectiveness of PCI compared with medical therapy for ST-elevation myocardial infarction (STEMI) and angina pectoris (AP) in Japan.
Methods and Results:We used Markov models for STEMI and AP to assess the costs and benefits associated with PCI or medical therapy from a health system perspective. We estimated the incremental cost-effectiveness ratio (ICER), expressed as qualityadjusted life-years (QALY), and ICER <¥5 m per QALY gained was judged to be cost-effective. The impact of PCI on cardiovascular events was based on previous publications. In STEMI patients, the ICER of PCI over medical treatment was ¥0.97 m per QALY gained. The cost-effectiveness probability of PCI was 99.9%. In AP patients, the ICER of fractional flow reserve (FFR)-guided PCI over medical treatment was ¥4.63 m per QALY gained. The cost-effectiveness probability of PCI was 50.4%. The ICER of FFR-guided PCI for asymptomatic patients was ¥23 m per QALY gained.
Conclusions:In STEMI patients, PCI was cost-effective compared with medical therapy. In AP patients, FFR-guided PCI for symptomatic patients could be cost-effective compared with medical therapy. FFR-guided PCI for asymptomatic patients with myocardial ischemia was not cost-effective.